Alveolar type II cell proliferation occurs after many forms of lung injury and is thought to play a critical role in alveolar epithelial repair. Keratinocyte growth factor/fibroblast growth factor 7 (KGF) has been shown to promote alveolar type II cell growth in primary culture and alveolar epithelial hyperplasia in vivo. In this study, we used immunohistochemical analysis to determine the intrapulmonary distribution and cellular localization of recombinant human KGF (rhKGF) instilled into the trachea of rats. 6 h after administration, immunoreactive KGF was observed within the lung parenchyma and along alveolar epithelial cell membranes. By 18-24 h, KGF was detected intracellularly in alveolar epithelial cells and intraalveolar macrophages. Immunoreactive KGF was not demonstrable 48 h after delivery or in lung sections from PBS-treated animals. Intratracheal instillation of 5 mg/kg rhKGF stimulated a marked, timedependent increase in the alveolar type II cell specific labeling index to a maximum level of 33±3% 48 h after rhKGF administration compared with 1.3+0.3% after PBS instillation. In addition, this increase in type II cell proliferation in vivo was documented by flow cytometric analysis of isolated type II cells which revealed a nearly fivefold increase in the proportion of cells traversing through the S and G2/ M phases of the cell cycle. To test the hypothesis that KGFs effects on type II cells in vivo might affect the response to lung injury, rats were treated with rhKGF and exposed to hyperoxia. Animals that received 1 or 5 mg/kg rhKGF exhibited dramatically reduced mortality (P < 0.001, for both doses). Survival for animals treated with 0.1 mg/kg rhKGF was not significantly different from either untreated rats or animals treated with heat-denatured rhKGF. The lungs of rhKGF-treated animals that survived hyperoxia exposure had minimal hemorrhage and no exudate within the intraalveolar space. These experiments established that intratracheal administration of rhKGF stimulated alveolar type II cell proliferation in vivo and reduced hyperoxia- 
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Keratinocyte growth factor/fibroblast growth factor-7
(KGF/FGF-7)' was identified as a fibroblast-derived, heparinbinding mitogen with activity in vitro restricted to epithelial cells (7, 8) . The unique target cell specificity was a consequence of the KGF receptor, a splice variant of FGF receptor 2 whose expression in cell lines was confined to epithelial cells (9) . These observations led to the hypothesis that KGF functioned as a paracrine mediator of mesenchymal-epithelial cell interactions affecting growth and development. This concept was supported by a series of subsequent experiments designed to investigate KGF expression and activity in whole animals and organ culture systems. In situ hybridization analysis of embryonic tissue localized KGF transcripts primarily to the stromal compartment of epithelial tissues, whereas KGF recep-tor expression was detected in the adjacent epithelial cells (10) (11) (12) . KGF expression was induced by testosterone in mesenchymal cells of the neonatal mouse seminal vesicle, where KGF was shown to mediate androgen-dependent branching of the glandular structures (13) . Systemic administration of recombinant human KGF (rhKGF) to adult rats specifically promoted epithelial hyperplasia in the lung, mammary gland, liver, and throughout much of the gastrointestinal tract (14) (15) (16) (17) . In addition, topical administration of rhKGF stimulated epidermal regeneration in different models of skin injury ( 18, 19) . Targeting expression of a dominant negative KGF receptor mutant to skin resulted in epidermal atrophy and delayed reepithelialization of skin wounds (20) . These latter findings were consistent with an earlier observation of dramatic KGF mRNA induction after the creation of full-thickness wounds in mouse skin (21) . Thus, the data strongly suggest that KGF participates in epithelial growth and repair processes during development and in the adult. KGF appears to have a particularly important role as a mediator of epithelial-mesenchymal cell interactions within the lung. KGF was isolated from the conditioned media of both fetal and adult lung fibroblasts in culture (7, 22) and was shown to stimulate alveolar type H cell proliferation in vitro (22). Transcripts for KGF and KGF receptor were detected in lung tissue from embryonic and adult animals (10) (11) (12) 14) . Branching morphogenesis and epithelial cell differentiation were blocked in transgenic mice expressing a dominant negative KGF receptor in alveolar type II cells (23) . These animals died immediately after birth due to the failure of lung parenchymal development. Consistent with this result, intratracheal instillation of KGF in normal rats stimulated alveolar epithelial hyperplasia and expression of proliferating cell nuclear antigen ( 14) .
Because of its activity in cutaneous wound healing and alveolar type H cell proliferation, KGF may play an important role in pulmonary repair. As a first step in testing the effect of rhKGF, we used immunohistochemical analysis to evaluate the distribution and cellular localization of immunoreactive KGF delivered to the lung by intratracheal instillation. The proliferative effect of rhKGF on alveolar type H cells was quantitated by double-label immunohistochemistry and flow cytometric cell cycle analysis. Finally, to determine whether rhKGF administration would alter the response to lung injury, rats were given rhKGF by intratracheal instillation and exposed to hyperoxia. rhKGF caused a highly significant, dose-dependent reduction in hyperoxia-induced lung injury and death. Methods rhKGF instillation. rhKGF was expressed and purified as described previously (14, 24) . Adult male Sprague-Dawley rats weighing 150-250 grams were given rhKGF by intratracheal instillation (25) . Briefly, rats were anesthetized with 87 mg/kg ketamine and 13 mg/kg xylazine by intraperitoneal injection. Once stage IV anesthesia was achieved, rats were placed in a supine position and orally intubated with an 18-gauge catheter under direct vision using a fiberoptic light source. Correct position of the catheter was ascertained by insufflation and observation of the chest and abdomen. Sedation was allowed to lighten slightly and then 3 ml of air and rhKGF in 0.6 ml of PBS were instilled via the endotracheal catheter with the rat in a vertical position. The catheter was removed when the animal awakened from anesthesia. Control animals were given 0.6 ml of PBS by intratracheal instillation and were processed in the same manner as the rhKGF-treated animals.
Immunohistochemical detection of KGF. To verify that rhKGF was delivered to the lung parenchyma and to determine the time course of tissue availability of rhKGF administered by intratracheal instillation, rats were killed 6, 18, 24, 48, and 72 h after receiving 5 mg/kg rhKGF or PBS. The lungs were excised, fixed with 10% buffered formalin at 20 cm H20 pressure, and embedded in paraffin. Sagittal 4-jim sections of the apical, middle, and basal portions of the left lung were incubated with 9 jig/ml of the IgG purified fraction of rabbit polyclonal antisera raised against a synthetic peptide corresponding to the carboxy-terminal sequence of hKGF (26) . After Flow cytometric cell cycle analysis of isolated alveolar type II cells. Type II cells were isolated from rats by elastase dissociation and differential adherence 48 h after the administration of either PBS or 5 mg/ kg rhKGF by intratracheal instillation (29) . Cell viability was determined by vital dye exclusion and the purity of alveolar type II cells was assessed by the presence of intracytoplasmic inclusions (29) . Alveolar type II cell purity was > 80% and cell viability was > 90% immediately after isolation. The freshly isolated cells were fixed in ice-cold 70% ethanol and then incubated with 1 mg/ml RNase A diluted in PBS at 37°C for 30 min and washed with PBS. They were then resuspended in 50 pg/ml propidium iodide in PBS for 30 min. The cytokinetic status of the isolated type II cells was determined by measurement of the DNA distribution using flow cytometry as described previously (30) .
Hyperoxia exposure. Hyperoxia exposures were performed as described previously (31) (32) (33) (34) (35) . This protocol was reviewed and approved by the Animal Care and Use Committee, Lakeside Veterans Administration Hospital. Sprague-Dawley rats were exposed to 100% oxygen at 3 liters/min in an airtight chamber. Throughout the exposure, they had free access to water and food. Drierite (CaSO4) was placed in the chamber to reduce the humidity and carbon dioxide was removed by adsorption to soda lime. Animals were carefully monitored four to five times daily for respiratory distress. Animals experiencing excessive labored breathing (a respiratory rate > 140 breaths/min or gasping, extension of the neck, and adduction of the forelimbs in a posture of labored respiration, use of abdominal muscles to assist breathing, or gasping agonal breathing) were killed by administration of pentobarbital and exsanguination by transection of the abdominal aorta. Animals surviving for 120 h in hyperoxia were killed in the same manner and the lungs excised and fixed for histopathologic examination.
To determine the concentration-dependent effect of KGF on survival in hyperoxia, groups of animals were given 0.1, 1, or 5 mg/kg rhKGF by intratracheal instillation. Control animals received either 5 mg/kg rhKGF that had been heat denatured by boiling for 30 min, which has been demonstrated to eliminate mitogenic activity in vitro (7, 22, 24), or were not treated. Between 5 and 11 animals were treated in each group. Survival data were expressed using Kaplan-Meier product limit curves which were compared using the log rank test (36) . exposed to hyperoxia (37, 38), we measured whole lung superoxide dismutase (SOD), Mn SOD, Cu/Zn SOD, and catalase enzymatic activities after the intratracheal instillation of either PBS or 5 mg/kg rhKGF and exposure to room air or hyperoxia for 48 h. Lungs were homogenized for 60 s in cold hypotonic buffer (5 mM potassium phosphate, pH 7.4) using a weight (gram) to volume (milliliter) ratio of 1:25. The homogenate was centrifuged at 500 g for 10 min, the pellet was discarded, and the supernatant was centrifuged at 20,000 g for 10 min. Aliquots of the supernatant were assayed for protein, SOD, and catalase. Protein was quantitated by the method of Lowry and co-workers (39) . SOD and catalase were measured spectrophotometrically (31, 40) . Data are expressed as the mean±SE and were compared using a two-tailed t test (Stat View).
Results
Immunoreactive KGF is detectable within the lung parenchyma after intratracheal instillation. Immunoreactive KGF protein was readily detected in rat lung sections obtained from animals 6 h after instillation of 5 mg/kg rhKGF (Fig. 1 A) . KGF was present within the lung parenchyma, suggesting that the instilled rhKGF was distributed distally into the intraalveolar spaces after injection into the trachea. A strong reaction product was homogeneously localized to the interstitium and both cuboidal and flattened alveolar epithelial cell membranes. By 18-24 h, the immunoreactive protein was more heterogeneously distributed along the basement membrane and was also found within alveolar epithelial cells and intraalveolar cells (Fig. 1, B and C). The latter probably were macrophages engaged in the phagocytic clearance of instilled rhKGF. The staining intensity was decreased compared with earlier time points. No immunoreactive KGF was detected 48-72 h after rhKGF administration. In PBS-treated animals, no KGF was observed. When either preimmune serum or peptide-absorbed antisera were used in the immunohistochemistry protocol, no immunoreactive KGF was detected in lung tissue sections from rhKGF-treated animals ( Fig. 1 D) . rhKGF administration stimulates type II cell proliferation in vivo. Intratracheal administration of 5 mg/kg rhKGF induced a time-dependent increase in type II cell proliferation (Fig. 2) (29, 30) . The percentage of cells in the proliferative phases of the cell cycle, S and G21M, increased from < 5% in PBS-treated animals to 23±+2% after rhKGF administration. Thus, these studies pro-vided quantitative evidence that intratracheal administration of rhKGF induced a dose-dependent increase in alveolar type II cell proliferation in vivo.
To determine whether rhKGF stimulated type II cell proliferation during hyperoxia, rats were given either PBS or 5 mg/ kg rhKGF and exposed to hyperoxia for 48 h. The type II cell labeling index was 12.7±3.0% in the rhKGF-treated animals and 5.0±2.4% in the PBS-treated animals. Therefore, intratracheal administration of rhKGF induced alveolar type II cell proliferation even with hyperoxia exposure, although the response was not as robust as that observed when animals were maintained in room air.
rhKGF administration decreases hyperoxia-induced mortality. To determine the effect of administration of 5 mg/kg rhKGF on hyperoxia-induced lung injury, rats were treated by intratracheal instillation and exposed to hyperoxia for up to 120 h. At necropsy after 120 h of hyperoxia exposure, the lungs of rhKGF-treated animals appeared grossly normal with few scattered areas of punctate hemorrhage on the pleural surface compared with the grossly hemorrhagic lungs of untreated rats dying between 55 and 80 h of hyperoxia exposure. None of the animals surviving 120 h of hyperoxia exposure had fluid within the pleural space, whereas pleural effusions were noted in all the animals that died during hyperoxia exposure. Histopathologically, the lungs of untreated animals demonstrated large areas of hemorrhage and interstitial edema (Fig. 3 A) . The intraalveolar space contained red blood cells, inflammatory cells, and proteinaceous exudate. In contrast, there was no intraalveolar exudate and minimal evidence of hemorrhage in the lungs of the animals treated with rhKGF who survived for 120 h in hyperoxia (Fig. 3 B) .
rhKGF at doses of 1 and 5 mg/kg significantly decreased hyperoxia-induced mortality (P < 0.001, for both doses) whereas survival for animals treated with 0.1 mg/kg rhKGF was not significantly different from either untreated rats or animals treated with heat-denatured rhKGF (P = 0.32 and P = 0.44, respectively) (Fig. 4) .
Antioxidant enzyme assays. To determine whether rhKGFinduced survival during hyperoxia exposure was mediated by an induction of whole lung antioxidant enzyme activity, rats were treated with either 5 mg/kg rhKGF or PBS and exposed to room air or hyperoxia for 48 h and whole lung enzyme activity was measured. rhKGF treatment did not affect whole lung specific catalase activity either after room air or hyperoxia exposure (Fig. 5 A) . After room air exposure, total SOD and Mn SOD activities were decreased in the rhKGF-treated animals compared with the PBS-treated group (P < 0.01 and P < 0.02, respectively) but there were no significant differences after hyperoxia exposure (Fig. 5 B) . In PBS-treated animals, there was a significant decrease in whole lung specific Mn SOD activity from 2.03±0.14 to 1.27±0.18 U/mg protein after hyperoxia exposure (P < 0.02) whereas, in the rhKGF-treated animals, there was no significant difference between room air and hyperoxia exposed animals, 1.36±0.15 vs. 1.02±0.27 U/mg protein, respectively (P = 0.33). Thus, based upon these studies, intratracheal rhKGF instillation did not increase whole lung specific activity of these antioxidant enzymes.
Discussion
In this report we demonstrated that rhKGF instilled into the trachea was distributed distally into the lung parenchyma and localized to alveolar epithelial cells and alveolar macrophages. rhKGF induced a dose-and time-dependent increase in alveolar type II cell proliferation which was quantitated by double-label immunohistochemistry. The alveolar type II cell specific labeling index reached a maximal level of 33 ±3% 48 h after administration of 5 mg/kg rhKGF and was 25-fold greater than in PBStreated animals. In another series of experiments, intratracheal administration of rhKGF markedly reduced the incidence of mortality in rats exposed to hyperoxia for 5 d. However, this protective effect could not be attributed to an increase in the activity of catalase or either total or Mn SOD because rhKGF instillation did not increase these enzyme activities in whole lung after 48 h of room air or hyperoxia exposure. These studies provided detailed quantitative evidence that KGF was a potent mitogen for alveolar type II cells in vivo and established that intratracheal administration of this factor could dramatically increase the survival of rats exposed to hyperoxia.
Interestingly, immunoreactive KGF was detectable only after the administration of rhKGF even though the KGF transcript is relatively abundant in normal lung tissue ( 10, 12, 14 The alveolar epithelial proliferative response has been used to quantify the severity of alveolar epithelial damage (42) . Hyperoxia causes extensive destruction of the alveolar epithelial cell lining in monkeys (43) and in humans (44). Although some investigations have not shown significant evidence of alveolar epithelial cell damage in rats exposed to hyperoxia (45) , other ultrastructural studies have demonstrated disruptions of the alveolar epithelium (46) . In rats exposed to hyperoxia for a short ier _Figure 4 (3, 5) , healing of the alveolar epithelium requires type II cell proliferation, intratracheal administration of rhKGF could preserve alveolar epithelial continuity by accelerating the alveolar type H cell proliferative response. In addition, replicating type II cells may be more resistant to the deleterious effects of oxygen as occurs in the neonatal rat (56, 57) . Independent of its effect on proliferation, KGF may promote the survival of epithelial cells by upregulating the expression of molecules like bcl-2 that are thought to inhibit cell death by reducing oxidant damage (58) . Preliminary experiments suggest that KGF reduced oxidant-induced DNA damage in type II cells in vitro (59) . KGF may also alter the differentiated function of alveolar type II cells including the synthesis and secretion of surfactant and surfactant proteins (Panos, R. J., and P. M. Bak, unpublished observations). Furthermore, because immunoreactive KGF was detected along both the flattened and cuboidal alveolar epithelial cells after intratracheal instillation, KGF may have a direct cytoprotective effect on type I cells as well.
Endogenous KGF in the lung probably functions as a homeostatic agent to maintain or restore the alveolar epithelium after lung injury. We believe that the administration of rhKGF reinforces the activity of endogenous KGF to ensure the integrity of the alveolar epithelium through the stimulation of type II cell proliferation and, potentially, other effects on alveolar epithelial cells that would promote their survival. The directed delivery of KGF to the lungs may provide a therapeutic strategy to enhance alveolar epithelial repair during lung damage due to hyperoxia or other injurious agents.
